S-1/A: Change Agents Corp. Files for Resale of Over 5.3M Shares

Sentiment:

Registration Statement (Form S-1/A) 16 September 2026 5:11 PM

Change Agents Corporation has filed an amendment to its S-1 registration statement to permit the resale of up to 5,375,797 shares of its common stock by selling stockholders.

Capital raiseThe company may receive up to $10,000,000 in aggregate gross proceeds from the sale of Put Shares under the ELOC Purchase Agreement.The company may also receive up to approximately $9,378 in aggregate gross proceeds if the ELOC Warrant and the Pre-Funded Warrants are exercised in full for cash.The company plans to raise capital through the sale of equity to implement its business plan, but there is no assurance that such financing will be available on satisfactory terms or at all.The company will need to raise significant additional capital to fund its operations and provide working capital.

Worse than expectedThe company's financial condition remains precarious, with a significant accumulated deficit and insufficient cash to cover 12 months of operations, raising substantial doubt about its ability to continue as a going concern.Despite regaining Nasdaq compliance, the company's reliance on continuous financing and the ongoing losses indicate a challenging financial outlook.The significant dilution potential from the Equity Purchase Agreement with Hudson Global Ventures, LLC, and the fixed purchase price of $2.00 per share (which is above the current trading price) present financial risks.

Summary

Change Agents Corporation (formerly Avalon GloboCare Corp.) is filing an amendment to its S-1 registration statement to allow for the resale of up to 5,375,797 shares of its common stock by various selling stockholders.
The shares being registered for resale include those issued under an Equity Purchase Agreement with Hudson Global Ventures, LLC, as well as shares from warrant exercises and other agreements.
The company is not selling any securities in this offering and will not receive any proceeds from the resale of shares by the selling stockholders, though it may receive up to $10 million from potential sales to Hudson under the Equity Purchase Agreement.
The company has a history of net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern, with current cash only sufficient for approximately one month of operations.
Change Agents Corporation recently regained compliance with Nasdaq's minimum bid price requirement, but faces ongoing risks related to its financial condition, operational history, and the evolving nature of its AI and consumer health technology segments.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's ongoing financial struggles, significant accumulated deficit, and substantial reliance on future financing, despite recent efforts to regain Nasdaq compliance.

Positives

Regained compliance with Nasdaq's Bid Price Rule (Listing Rule 5550(a)(2)) for continued listing on The Nasdaq Capital Market.
The company is actively developing and commercializing two business segments: AI software (Avalon Quantum AI) and consumer health technology (Keto Air breathalyzer).
Expansion into new technology areas such as drone interception and surveillance AI enhanced technology solutions through Autonomous Air Defense Systems LLC.
The Catch-Up AI platform is expected to launch Phase 2 in Q3 2026, expanding its addressable market.
The ELOC Purchase Agreement provides a potential source of up to $10 million in aggregate gross proceeds for the company, at its discretion.

Negatives

The company has a history of net losses and an accumulated deficit of approximately $112.6 million as of June 30, 2026, raising substantial doubt about its ability to continue as a going concern.
As of September 11, 2026, the company had approximately $172,000 in cash, sufficient for only about one month of operations, requiring approximately $5 million for 12 months of operations.
The company has approximately $2.7 million in outstanding indebtedness as of September 11, 2026.
The company has not generated sustainable revenue since inception and anticipates it will take approximately one year to generate meaningful revenue from its Catch-Up platform.
The company faces intense competition in both its business segments from companies with substantially greater resources.

Risks

The company has a limited operating history in its current business segments, making it difficult to evaluate its future prospects.
There is substantial doubt about the company's ability to continue as a going concern due to recurring net losses, negative cash flows, and insufficient cash to cover operating expenses for the next 12 months.
The company's business is subject to rapid technological change, and failure to adapt could negatively impact its operations.
The use of AI in its platform may give rise to legal liability, reputational harm, and regulatory scrutiny, including risks related to harmful content, inaccuracies, and intellectual property infringement.
The company's Catch-Up platform's AI avatar feature implicates state right of publicity laws and biometric privacy laws, potentially leading to significant legal liability.
The company may not be able to adequately protect its intellectual property rights, and competitors may offer similar products and services.
Laws and regulations governing artificial intelligence are rapidly evolving, and compliance may be costly and uncertain.
The sale of a substantial number of shares by selling stockholders could cause the trading price of the company's common stock to decline.

Future Outlook

The company's future outlook is heavily dependent on its ability to secure additional financing to fund its operations and growth initiatives, including the development and commercialization of its AI and consumer health products. The company anticipates needing to raise significant additional capital to continue its operations.

Management Comments

We believe our diverse and evolving portfolio of commercial activities reflects our ongoing commitment to identifying and building value-oriented technology businesses for the benefit of its stockholders.
We are actively seeking complementary bolt-on AI acquisitions that could generate near-term revenue to supplement our current operations as both segments continue to develop.

Industry Context

StockSavvy.ai notes that Change Agents Corporation operates in the rapidly evolving AI and consumer health technology sectors. The AI sector is characterized by intense competition and rapid technological advancements, while the consumer health market is influenced by consumer trends and regulatory landscapes. The company's strategy to pursue AI acquisitions and expand into defense technology reflects a dynamic approach to market opportunities.

Comparison to Industry Standards

The filing mentions a McKinsey & Company report indicating that 50% of consumers use AI-powered search for buying decisions and 60% of searches end without a click, highlighting the shift towards AI-driven answers.
The company competes with numerous technology companies in the generative AI space, many of whom have significantly larger market presence, greater name recognition, and more substantial financial and technical resources.
In the consumer health technology segment, competitors include manufacturers and distributors of urine-based ketone test strips and other breath-based ketone monitoring devices, many with established retail distribution networks.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Director Resignations	William B. Stilley III, Wilbert J. Tauzin II, and Tevi Troy resigned from the Board of Directors and all Board committees on February 24, 2026.	2026-02-24	Reduced board size and necessitated appointments to committees.
Director Appointments	Lourdes Felix appointed as member and Chair of the Audit Committee and member of the Compensation Committee. Michael Mathews appointed as member of Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, and Chair of the Nominating and Corporate Governance Committee. Steven Sanders appointed as Lead Independent Director and Chair of the Compensation Committee.	2026-02-24	Restructured committee leadership and ensured independent director oversight.
Name Change	Company name changed from Avalon GloboCare Corp. to Change Agents Corporation.	2026-07-20	Reflects strategic shift and rebranding; trading symbol changed from ALBT to CHGA.

Legal Proceedings

On October 28, 2019, Research Institute at Nationwide Childrens Hospital filed a Complaint alleging misappropriation of trade secrets and violation of trade secrets acts. A settlement agreement was reached on June 7, 2022, involving payments and profit-sharing.
The company is subject to various data privacy and security laws, including the California Consumer Privacy Act (CCPA) and potentially biometric data privacy laws like BIPA, with ongoing compliance obligations.

Related Party Transactions

Consulting services provided by Wilbert Tauzin (former director) and his son.
Sale of 100% of Avalon RT 9 Properties, LLC to Wenzhao Lu (Chairman of the Board) for approximately $9,000,000 on February 18, 2026.
Exchange of 9,000 shares of Series A Preferred Stock for 5,000 shares of Series D Preferred Stock with Wenzhao Lu on January 9, 2025.
Lease of office space from Wenzhao Lu commencing March 1, 2026.
Issuance of 18,000 shares of common stock to Agile Lending LLC as consideration for a forbearance letter agreement.

Stakeholder Impact

Shareholders may experience substantial dilution due to potential future sales of common stock under the ELOC Purchase Agreement and the exercise of outstanding options, warrants, and convertible securities.
The company's ability to continue as a going concern directly impacts all stakeholders, including employees, creditors, and investors.
The company's reliance on future financing could affect its ability to meet operational and financial obligations, potentially impacting creditors and suppliers.
The resale of a large number of shares by selling stockholders could depress the market price of the company's common stock, affecting current shareholders.

Next Steps

The company intends to seek stockholder approval for the issuance of shares upon conversion of Series E Preferred Stock.
The company intends to pursue a phased commercial launch strategy following the completion of Phase 2 development for the Catch-Up platform.
The company will continue to evaluate possible AI acquisitions that could generate near-term revenue.
The company will continue to maintain and prosecute its cellular therapy patent portfolio.
The company intends to evaluate the commercial and strategic value of converting its provisional AI patent applications into non-provisional applications.

Key Dates

Date	Description
2025-12-15	Acquisition of RPM Interactive, Inc. and formation of Avalon Quantum AI, LLC.
2026-07-22	Execution of the Equity Purchase Agreement with Hudson Global Ventures, LLC.
2026-08-21	Amendment No. 1 to Equity Purchase Agreement executed.
2026-08-28	Company effectuated a 1-for-20 reverse stock split.
2026-09-09	Amendment No. 2 to Equity Purchase Agreement executed.
2026-09-15	Company received notice from Nasdaq that it had regained compliance with the Bid Price Rule.
2026-09-16	Date of the preliminary prospectus.

Recommendation

hold

While the company has regained Nasdaq compliance and is pursuing growth in AI and health tech, its precarious financial situation, significant accumulated deficit, and reliance on future financing present substantial risks. The potential for significant dilution from the ELOC agreement and the ongoing operational losses warrant a cautious approach. A 'hold' recommendation reflects the speculative nature of the investment, balancing potential upside from new ventures against considerable financial headwinds.

Keywords

Change Agents Corporation, S-1/A Filing, Resale of Shares, Hudson Global Ventures, Equity Purchase Agreement, Common Stock, Nasdaq Compliance, AI Software

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.